SN 2
Based on 5 publication(s) in Google Scholar
SN 2 is a potent activator of TRPML3 ion channel with an EC50 of 1.8 μM. SN 2 also acts as a potent inhibitor of Dengue virus 2 (DENV2) and Zika virus (ZIKV).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.93%
- CAS No.: 823218-99-1
- Formule: C17H21NO
- Masse moléculaire:255.35
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Neuronal Signaling Compound Library
HY-L013
-
Antiviral Compound Library
HY-L027
-
Mechanoreceptors Compound Library
HY-L095
-
Pain-Related Compound Library
HY-L139
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Ion Channel Compound Library
HY-L166
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) SN 2
More
Customer Validation & Images
-
RT-PCR
-
WB
Activité biologique
EC50: 1.8±0.13 μM (TRPML3), >29.9 μM (TRPML1)[1]
The conductance of TRPML3 channels is estimate, when activated with 10 µM SN-2 is approximately 10 pS at −80 mV. TRPML3-expressing HEK293 cells are perfused with a series starting with compound alone (in SBS), with compound in ELS, and finally with ELS alone. Two representative compounds, SF-24 and SN-2, are tested. SF-24 is one of the least effective compounds, and SN-2 is one of the most active ones. SN-2 has a similar synergistic effect, also reaching up-to 10-fold enhancement of the combined response when compared with the individual responses, reaching average current densities of up to 3 nA/pF at −80 mV. Dominant negative TRPML3(D458K) is highly effective in eliminating SN-2-induced activity in epidermal melanocytes, suggesting that SN-2 activates a channel that is not responsive in presence of TRPML3(D458K). Such a dominant negative action might be attributed to potential heteromerization of TRPML3(D458K) with an SN-2-responsive channel[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 823218-99-1
-
Appearance Solid
-
Masse moléculaire 255.35
-
Formule C17H21NO
-
Color White to off-white
-
SMILES
CC(C=C(C)C=C1C)=C1C2=NOC3C2C4CC3CC4
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Antiviral Res
ML-SA1 and SN-2 inhibit endocytosed viruses through regulating TRPML channel expression and activity. [Abstract]2021 Nov:195:105193. PMID: 34687820 -
Antiviral Res
ML-SA1, a selective TRPML agonist, inhibits DENV2 and ZIKV by promoting lysosomal acidification and protease activity. [Abstract]2020 Oct;182:104922. PMID: 32858116
SN 2 purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2020 Oct;182:104922. [Abstract]
SN-2 treatment could decrease both DENV2 RNA and DENV2 E protein in a dose-dependent manner under noncytotoxic concentrations in A549 cells. SN-2 treatment also dose-dependently inhibits both ZIKV RNA and ZIKV E protein in A549 cells.
-
Gene
2023 May 15:864:147291. PMID: 36813061
SN 2 purchased from MedChemExpress. Usage Cited in: Gene. 2023 May 15:864:147291. [Abstract]
SN-2 (5, 10, 20 μM) dose-dependently upregulates the expression of three inflammatory marker genes, IL-1β, IL-6 and TNFα in A549 cells.
-
-
Solvant et solubilité
DMSO : 100 mg/mL (391.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.79 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.79 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Grimm C, et al. Small molecule activators of TRPML3. Chem Biol. 2010 Feb 26;17(2):135-48. [Content Brief]
[2]. Zhiqiang Xia, et al. ML-SA1, a selective TRPML agonist, inhibits DENV2 and ZIKV by promoting lysosomal acidification and protease activity. Antiviral Res. 2020 Aug 26;104922. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.9162 mL | 19.5810 mL | 39.1619 mL | 97.9048 mL |
| 5 mM | 0.7832 mL | 3.9162 mL | 7.8324 mL | 19.5810 mL | |
| 10 mM | 0.3916 mL | 1.9581 mL | 3.9162 mL | 9.7905 mL | |
| 15 mM | 0.2611 mL | 1.3054 mL | 2.6108 mL | 6.5270 mL | |
| 20 mM | 0.1958 mL | 0.9790 mL | 1.9581 mL | 4.8952 mL | |
| 25 mM | 0.1566 mL | 0.7832 mL | 1.5665 mL | 3.9162 mL | |
| 30 mM | 0.1305 mL | 0.6527 mL | 1.3054 mL | 3.2635 mL | |
| 40 mM | 0.0979 mL | 0.4895 mL | 0.9790 mL | 2.4476 mL | |
| 50 mM | 0.0783 mL | 0.3916 mL | 0.7832 mL | 1.9581 mL | |
| 60 mM | 0.0653 mL | 0.3263 mL | 0.6527 mL | 1.6317 mL | |
| 80 mM | 0.0490 mL | 0.2448 mL | 0.4895 mL | 1.2238 mL | |
| 100 mM | 0.0392 mL | 0.1958 mL | 0.3916 mL | 0.9790 mL |
SN 2 Related Classifications
HY-16696 Related Classifications
Powered by Bioz